ClinicalTrials.gg
CompletedNCT02970110Updated Mar 18, 2022

Specimen Collection Study for H. Pylori Testing

An observational study in Helicobacter Infections, sponsored by Biomerica. Completed at 4 sites in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-18.

Sponsored by Biomerica · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
98
Ages
21 Years to 75 Years
Sex
All
01

Study summary

The objective of this study is to acquire human specimens from subjects undergoing routine endoscopy with gastric biopsy for the diagnosis of active H. pylori infection.

Read the detailed description

This is a prospective study designed to acquire and bank human specimens from subjects who are scheduled for routine upper endoscopy for symptoms such as dyspepsia. This study will be conducted at a minimum of 2 sites in the United States. Investigator sites will enroll prospective subjects who meet the inclusion / exclusion criteria. A case report form (CRF) provided by the sponsor will be used to capture basic demographic information (DOB, age, gender, race/ethnicity), medication history, and related clinical information. The CRFs will also record the results of the following tests performed with the gastric biopsy tissue specimens: histology and rapid urease test (RUT).

02

Conditions studied

  • Helicobacter Infections
03

In context

Helicobacter Infections

53 studies on the registry are indexed under Helicobacter Infections; 9 are open to participants now.

This study's enrollment of 98 is below the median of 235 across 14 observational studies indexed under Helicobacter Infections.

Browse Helicobacter Infections studies →

Lead sponsor

Biomerica is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will consist of subjects scheduled for routine upper endoscopy for upper gastrointestinal tract symptoms such as dyspepsia. All prospective subjects must be off of proton-pump inhibitors, antibiotics, and bismuth for at least 2 weeks prior to submission of the stool specimen and undergoing endoscopy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 21 and to 75 years.
  • Able to read, speak, and understand English or have access to a translator in subject's native language.
  • Patients without prior H. pylori eradication treatment.
  • Currently not on proton pump inhibitors, antibiotics or bismuth

    • Discontinuation at least 2 weeks prior to endoscopy and specimen collection.
  • Present with signs and symptoms of dyspepsia [e.g. upper abdominal discomfort or pain]
  • Undergo gastric as part of routine care
  • Physician able to provide histology and rapid urease result on biopsy specimens.

Exclusion criteria

Exclusion Criteria:

  • Aged less than 21 years old or older than 75 years
  • Unable to provide consent.
  • Patients with a history of prior H. pylori eradication therapy.
  • Currently on proton pump inhibitors, antibiotics or bismuth and cannot or will not discontinue
  • Previous upper gastrointestinal surgery, such as bariatric surgery, Nissen fundoplication, or Roux-en-Y.
  • Any unstable or poorly-controlled medical or psychiatric condition.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
98 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Non-invasive collection procedure

    This study is designed to collect specimens to supplement repository specimens for product validation purposes. The endoscopy results and specimens will be used in a future clinical trial of a non-invasive in vitro diagnostic assay for the detection of H. pylori antigen. institutional review board approval is sought in order to be able to use human specimens for validation of in vitro diagnostics.

    Time frame: 1 year

07

Study locations

4 sites
  • Del Sol Research Management, Inc.
    Tucson, Arizona 85712, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Medley Research Associates
    Medley, Florida 33166, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212-1610, United States
08

References and documents

Individual participant data

Plan to share: No — Demographics including age, gender, geographical location, histology and RUT results collected in this study will be shared with researchers involved with a future evaluation of an in vitro diagnostic device product in development at Biomerica.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Mar 2020, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2016
First posted
Nov 21, 2016
StartActual
Feb 27, 2017
Primary completionActual
Mar 1, 2020
CompletionActual
Mar 1, 2020
Last update
Mar 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02970110
Lead sponsor
Biomerica
Responsible party
Sponsor
First posted
Nov 21, 2016
Start date
Feb 27, 2017
Primary completion
Mar 1, 2020
Completion
Mar 1, 2020
Last update
Mar 18, 2022

Study contacts

James R Buxbaum, M.D.
principal investigator · University of Southern California, Los Angeles County Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion